Risk factors

Fold Holdings expanded its product suite with the Fold Credit Card and Employee Bitcoin Bonus program while maintaining a significant bitcoin treasury.

Gap Inc. added specific risks concerning new U.S. tariffs and the integration of artificial intelligence into its operations. The company consolidated disclosures on debt, data security, and sustainability matters. Supply chain and inventory management risks were refined to emphasize trend forecasting and vendor dependencies.

Pipeline expanded to include MRT-8102 alongside MRT-2359 and Novartis-partnered MRT-6160 moving to Phase 2.

PROSERA missed its primary endpoint, putting seralutinib’s FDA path, further trials, financing needs, and commercialization in doubt.

AI risks now emphasize regulation, copyright, personal-data compliance, and litigation involving GitLab Duo.

Gaxos.ai pivoted away from NFT platforms and digital assets toward artificial intelligence markets.

The company relies heavily on a top client representing 10.5% of revenue in 2025. Cost management through Project Elevate remains central to operations. Client concentration and leadership turnover continue to pose key risks.

HealthEquity expanded risks around marketplace partnerships and compounded GLP-1 weight loss regulations, increased AI fraud threats, and updated revenue figures.

Mr. Lazar took control via 111.0 million convertible preferred shares representing 96.4% dilution. Patient enrollment in the Decoy20 Combination Study with BeiGene was discontinued. Cash of $8.5 million funds operations only into Q2 2026.

Newtek is now the largest customer at 32.5% of revenue, and its terminable referral arrangement is an explicit growth dependency.

The company reported thin operating income alongside an accumulated deficit of $104.3 million as of December 31, 2025.

Kalaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead candidate TH103 for retinal diseases like nAMD.